EE: Harris-Benedict: Obese and Nonobese (2005)

Citation:
 
Study Design:
Class:
- Click here for explanation of classification scheme.
Quality Rating:
Research Purpose:

To compare measured resting energy expenditure with calculated REE using actual, ideal, and adjusted body wt in the HBE and the IJE in obese females.

Inclusion Criteria:

1. Understand and give written consent

2. Diseases in subjects that were allowed: heart disease, endocrine problems, diabetes mellitus, HIV/AIDS, or other major diseases affecting immune system function

3. Medications allowed: any drugs known to affect metabolic rate.

Exclusion Criteria:

1. Refusal to consent

2. Not meeting inclusion criteria

3. Participants who smoked more than 6 cigarettes per day or exercised heavily

4. Pregnant or lactating women

Description of Study Protocol:

Definitions:

Steady state”- 3 consecutive 30s VO2/L readings were within 0.01L and hwere VO2 values were no longer dropping.

Obesity of defined as greater than 125% ideal body wt

Terms:

HBE-the Harris-Benedict equation

IJE-the Ireton-Jones equation

MREE-measured resting energy expenditure

IBW-ideal body weight

ABW-actual body weight

AdjBW-adjusted body weight

“RMPSE”-root mean squared prediction error

Anthropometrics

Ht measured ? yes

Wt measured ? yes

Fat-free mass measured? yes

Lean mass, fat mass, BMI

CLINICAL:

Monitored heart rate? yes

Body temperature? yes

Medications administered? no

Resting energy expenditure:

IC type: open circuit

Equipment of Calibration: yes

Coefficient of variation using std gases: yes

Rest before measure (state length of time rested if available): 30 min

Measurement length: 1 continuous measure

Steady state: the measurements was completed when the participant reached a stead state

Fasting length: 12h; : none during measurements

Exercise restrictions XX hr prior to test? 24h;

Room temp: 21-22 °C

No. of measures within the measurement period: continuous measurements

Were some measures eliminated? no

Were a set of measurements averaged? no

Coefficient of variation in subjects measures? no

Training of measurer? no

Subject training of measuring process? no

DIETARY

All subjects fast 12 h before IC measurements. Dietary intake prior to IC studies were not controlled

Intervening factor:

Menstrual cycle was not considered.

Blinding used (if applicable): None

Statistical Analysis

Descriptive statistics

Pearson’s correlation

Paired t test

Stepwise linear regressions analysis

RMPSE was calculated to determine how close calculated REE values compared to the MREE for each person. The smaller the RMSPE, the closer the calculated value is to the measured values. RMSPE is a good indicator of the accuracy of the prediction equations for each person, rather than for the sample as a whole.

Data Collection Summary:

Outcome(s) and other measures

1. Measured REE

2. Predicted RMR using: HBE (using IBW, ABW, AdjBW) and IJE

3. Independent variables of weight, height, age, BMI,and fat-free mass, fat mass

Blinding Used:  None

Description of Actual Data Sample:

N= 19 women, aged 19-38 yr   (29.5 +/-5.38 y)

Healthy, premenopausal , young, Caucasian women

17 were nonsmokers, 2 smoked less than 6 cigarettes/d

Summary of Results:

ANTHROPOMETRIC (mean ± SD)          

 

Mean ± SD     

Range

Ht,cm     

166 ±4.1       

158.5 - 175.9

Wt,kg     

98.0 ± 23.4    

70.9 - 159.1

BMI        

35.3 ± 8.4     

26.0 - 59.1

FM,kg    

41.3 ± 14.7    

24.8 - 81.8

FFM,kg  

56.7 ± 9.3      

45.8 – 77.3

%body fat 

41.2 ± 5.0   

31.6-51.4

MREE   

1359.2 ± 252.4  

941.0 – 1775.0

HBE(IBW)

1416.3 ± 50.3 

1333.0 – 1514.0

HBE(ABW)*

1755.4 ± 217.9  

1530.0 – 2346.0

HBE(AdjBW)**

1505.5 ± 75.6 

1385.0 – 1661.0

Ireton-Jones Eqn*

1868.5 ± 257.1  

1571.0 – 2541.0

                 

 

*significantly different from MREE at p<0.0001 level

** significantly different from MREE at P<0.05 level

There was no significant difference between MREE and REE calculated with HBE using IBW.  REE calculated with HBE adjusted and actual body wt were significantly higher than MREE by 11% (p<0.05) and 29% (p<0.0001), respectively; REE calculated with IJE was significantly higher than measured REE by 37% (P<0.0001)

Root Mean Squared Prediction Error (mean ±SD)

HBE using adjusted body wt had the lowest RMSPE. Stepwise regressions analysis resulted in the following prediction equation for REE:

REE= 17.5(LMB) + 368.7,

       R=0.64

Author Conclusion:

“Using ABW in the HBE to estimate energy expenditure in obese women should be avoided because it consistently overestimates energy requirements. Using ABW in the equation assumes the excess wt is the same composition as that of a lean person. Using ABW does not compensate for the considerable amount of FFM and the slowed metabolic activity of adipose tissue.”

“HBE using AdjBW was greater than MREE; however, the difference (11%) was much less than the difference between HBE using ABW (29%) and the IJE (37%).”

“There was no difference between HBE using IBW and measured REE; however, RMSPE values indicate that HBE using AdjBW was the most accurate predictor of measured REE, followed closely by HBE using IBW.”

“The IJE overestimated REE of our participants, and had the highest RMSPE value, indicating that it was the least accurate of the equations used.”

“The present study provides evidence that using HBE with IBW or AdjBW are better than the IJE or HBE using ABW to use when estimating REE in obese women.”

Funding Source:
Industry:
Wyeth-Ayerst Pharmaceuticals, NeoRX Corporation
Pharmaceutical/Dietary Supplement Company:
Other:
University/Hospital: Washington State University, University of Dayton
Reviewer Comments:

Strengths:

    • Compared MREE with HB with IBW, ABW and AdjBW.
    • Appropriate, sophisticated statistics.
    • Smoking status, physical activity were monitored.
    • Conclusions were supported by results, and were considered with its small sample size.
    • A thorough discussion of different equations based on study results.

Generalizability/Weaknesses:

    • Relatively small sample size for validations study.  Results only applied to healthy, young, premenopausal obese women.
    • Limitations were not fully addressed.
Quality Criteria Checklist: Primary Research
Relevance Questions
  1. Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) Yes
  2. Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? Yes
  3. Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? Yes
  4. Is the intervention or procedure feasible? (NA for some epidemiological studies) Yes
 
Validity Questions
1. Was the research question clearly stated? Yes
  1.1. Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? N/A
  1.2. Was (were) the outcome(s) [dependent variable(s)] clearly indicated? N/A
  1.3. Were the target population and setting specified? N/A
2. Was the selection of study subjects/patients free from bias? Yes
  2.1. Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? N/A
  2.2. Were criteria applied equally to all study groups? N/A
  2.3. Were health, demographics, and other characteristics of subjects described? N/A
  2.4. Were the subjects/patients a representative sample of the relevant population? N/A
3. Were study groups comparable? N/A
  3.1. Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) N/A
  3.2. Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? N/A
  3.3. Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) N/A
  3.4. If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? N/A
  3.5. If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) N/A
  3.6. If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? N/A
4. Was method of handling withdrawals described? No
  4.1. Were follow-up methods described and the same for all groups? N/A
  4.2. Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) N/A
  4.3. Were all enrolled subjects/patients (in the original sample) accounted for? N/A
  4.4. Were reasons for withdrawals similar across groups? N/A
  4.5. If diagnostic test, was decision to perform reference test not dependent on results of test under study? N/A
5. Was blinding used to prevent introduction of bias? Yes
  5.1. In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? N/A
  5.2. Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) N/A
  5.3. In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? N/A
  5.4. In case control study, was case definition explicit and case ascertainment not influenced by exposure status? N/A
  5.5. In diagnostic study, were test results blinded to patient history and other test results? N/A
6. Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? Yes
  6.1. In RCT or other intervention trial, were protocols described for all regimens studied? N/A
  6.2. In observational study, were interventions, study settings, and clinicians/provider described? N/A
  6.3. Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? N/A
  6.4. Was the amount of exposure and, if relevant, subject/patient compliance measured? N/A
  6.5. Were co-interventions (e.g., ancillary treatments, other therapies) described? N/A
  6.6. Were extra or unplanned treatments described? N/A
  6.7. Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? N/A
  6.8. In diagnostic study, were details of test administration and replication sufficient? N/A
7. Were outcomes clearly defined and the measurements valid and reliable? Yes
  7.1. Were primary and secondary endpoints described and relevant to the question? N/A
  7.2. Were nutrition measures appropriate to question and outcomes of concern? N/A
  7.3. Was the period of follow-up long enough for important outcome(s) to occur? N/A
  7.4. Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? N/A
  7.5. Was the measurement of effect at an appropriate level of precision? N/A
  7.6. Were other factors accounted for (measured) that could affect outcomes? N/A
  7.7. Were the measurements conducted consistently across groups? N/A
8. Was the statistical analysis appropriate for the study design and type of outcome indicators? Yes
  8.1. Were statistical analyses adequately described and the results reported appropriately? N/A
  8.2. Were correct statistical tests used and assumptions of test not violated? N/A
  8.3. Were statistics reported with levels of significance and/or confidence intervals? N/A
  8.4. Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? N/A
  8.5. Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? N/A
  8.6. Was clinical significance as well as statistical significance reported? N/A
  8.7. If negative findings, was a power calculation reported to address type 2 error? N/A
9. Are conclusions supported by results with biases and limitations taken into consideration? Yes
  9.1. Is there a discussion of findings? N/A
  9.2. Are biases and study limitations identified and discussed? N/A
10. Is bias due to study's funding or sponsorship unlikely? Yes
  10.1. Were sources of funding and investigators' affiliations described? N/A
  10.2. Was the study free from apparent conflict of interest? N/A